People · Operator
Named in public records as an officer, director or promoter · active 2008–2012 · Manufacturing, Healthtech, Other Health Care, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ingersoll-Rand Global Holding CO LTD | — | Manufacturing | Growth/Late | $3.5B | $26.4B | 2008 |
| Avantis Medical Systems Inc | — | Healthtech | Series B | $47.5M | $56.7M | 2011 |
| Salient Surgical Technologies, Inc. | — | Other Health Care | Series A | $18.4M | $302.7M | 2009 |
| Abbeymoor Medical Inc | — | Biotechnology | Seed | $1.3M | $59.5M | 2008 |
Richard Randall at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Richard Randall on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Brown | 1 | 25 |
| David Silverman | 1 | 15 |
| Jay Schmelter | 1 | 6 |
| Howard Palefsky | 1 | 4 |
| Daniel George | 1 | 4 |
| Scott Dodson | 1 | 3 |
| John J. Savarese | 1 | 3 |
| Robert Griffin | 1 | 3 |
| Michael Mayer | 1 | 3 |
| Thomas Fogarty | 1 | 3 |
| J. Neal Armstrong | 1 | 3 |
| John Reed | 1 | 2 |
| Mark Roby | 1 | 2 |
| Thomas J. Fogarty | 1 | 2 |
| Robert Wah | 1 | 2 |
| Robert L Griffin | 1 | 2 |
| Daniel Turner III | 1 | 2 |
| Camran Nezhat | 1 | 1 |
| Matthew Jenusaitis | 1 | 1 |
| Camran J. Nezhat | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.